Suven Life Sciences share news, announcements and annual reports
NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap
Suven Life Sciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹258.85down ₹5.35 (2.03%)BSE ₹258.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹264.20.
30 Oct: open ₹263.50, high ₹265.65, low ₹257.00
52-week range of traded prices to 30 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,314 Cr806th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −100.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −63.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,27,67850.0% delivered
Suven Life Sciences board meetings
122 filed, newest first. Page 2 of 3.
Apr 2019
15 Apr · Board meeting
Mar 2019
9 Mar · Board meeting
4 Mar · Board meeting
Feb 2019
5 Feb · Board meeting
5 Feb · Board meeting
Jan 2019
Nov 2018
14 Nov · Board meeting
Aug 2018
14 Aug · Board meeting
6 Aug · Board meeting
May 2018
15 May · Board meeting
Jan 2018
Nov 2017
11 Nov · Board meeting
Aug 2017
14 Aug · Board meeting
May 2017
13 May · Board meeting
Feb 2017
1 Feb · Board meeting
Jan 2017
Nov 2016
Aug 2016
May 2016
Mar 2016
Feb 2016
Nov 2015
Aug 2015
14 Aug · Board meeting
Board in its meeting held on August 14, 2015 has authorized to create an overseas subsidiary with an initial investment of US$ 25 Mn for clinical development and commercialization of Suven pipeline and in-licensed molecules.
May 2015
Feb 2015
10 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 10, 2015 has approved: Mr. P. Subba Rao, the GM (Finance & Costing) has been appointed as Chief Financial Officer (CFO) of the Company by the Board.2 Feb · Board meeting
To consider, inter alia, and take on record the Un-audited Financial Results for the third quarter ended December 31, 2014.
Sep 2014
Aug 2014
4 Aug · Board meeting
To consider, inter alia, and take on record the Un-audited Financial Results for the first quarter ended June 30, 2014. Further that Trading window for dealing in the securities of the company was closed from August 04, 2014 to August 13, 2014. Trading window will be opened from August 14, 2014.
May 2014
Jan 2014
Nov 2013
Oct 2013
Aug 2013
5 Aug · Board meeting
To consider, inter alia, and take on record the Un-audited Financial Results for the first quarter ended June 30, 2013.
May 2013
Feb 2013
4 Feb · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the third quarter ended December 31, 2012.
Nov 2012
5 Nov · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the second quarter ended September 30, 2012.
Aug 2012
6 Aug · Board meeting
To consider, inter alia and to take on record the following matters : (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2012; (2) To recommend dividend for the financial year ended March 31, 2012, if any; (3) To announce Book Closure for the purpose of AGM; (4) To consider and take on record the Un-audited Financial Results for the first quarter ended June 30, 2012.
Apr 2012
25 Apr · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the quarter ended March 31, 2012.
Jan 2012
31 Jan · Board meeting
W.e.f. December 31, 2011, Suven Nishtaa Pharma Pvt. Ltd. has become a wholly owned subsidiary company of Suven Life Sciences Limited. Further the Company has informed that the Board of Directors of the Company at its meeting held on January 31, 2012, inter alia, has given its consent for the amalgamation of the said wholly owned subsidiary - Suven Nishtaa Pharma Private Limited with the holding Company - Suven Life Sciences Limited, subject to the approval of the scheme by the Honble High Court of Andhra Pradesh. Consequent to the above, there will be no issue of shares pursuant to the merger, since the Company which is being proposed to be merged with the holding Company is a wholly owned subsidiary.23 Jan · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the third quarter ended December 31, 2011.
Oct 2011
21 Oct · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the second quarter ended September 30, 2011.
Aug 2011
1 Aug · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the first Quarter ended June 30, 2011.
May 2011
19 May · Board meeting
To consider, inter alia, and take on record the following matters : (1) To consider and approve the Audited Annual Accounts for the year ended March 31, 2011; (2) To consider and recommend dividend if any, for the financial year 2010-2011.
Jan 2011
21 Jan · Board meeting
To consider, inter alia and to take on record the Un-audited Financial Results for the Third Quarter ended December 31, 2010.